|
T15238 |
Epoprostenol sodium
|
Prostaglandin I2 sodium salt,Prostacyclin sodium salt,Flolan |
Others
|
|
Epoprostenol sodium is a potent inhibitor of platelet aggregation used in pulmonary hypertension and transplantation. |
|
T26745 |
BAY 73-1449
|
BAY-73-1449,BAY73-1449 |
Others
|
|
BAY-73-1449 is an antagonist of prostacyclin receptor. |
|
T36774 |
13,14-dehydro-15-cyclohexyl Carbaprostacyclin
|
|
Others
|
|
13,14-dehydro-15-cyclohexyl Carbaprostacyclin is a chemically stable analog of PGI2. It inhibits the ADP-induced aggregation of human platelets with an ED50 of about 40 nM in PRP and 77 nM in washed platelets, which is c... |
|
T36236 |
5-cis Carbaprostacyclin
|
|
Others
|
|
5-cis Carbaprostacyclin is a stable analog of PGI2 and an isomer of carbaprostacyclin. It is a weak inhibitor of human platelet aggregation with an IC50 of 2.8 μM compared to 0.3 μM for carbaprostacyclin. 5-cis Carbapros... |
|
T69360 |
RO3244794
|
|
Prostaglandin Receptor
|
|
RO3244794 is a selective prostacyclin (IP) receptor antagonist that can be used to study liver injury. |
|
T4635 |
Ralinepag
|
APD811 |
Others
,
Prostaglandin Receptor
|
|
Ralinepag (APD811) is a potent, orally bioavailable agonist of non-prostanoid prostacyclin (IP) receptor, with EC50s of 8.5 nM, 530 nM and 850 nM for human and rat IP receptor and human DP1 receptor, respectively. |
|
T3216 |
Selexipag
|
NS-304,ACT-293987,Uptravi |
Others
,
Prostaglandin Receptor
|
|
Selexipag (ACT-293987)(NS-304) is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary arterial hypertension (PAH). |
|
T21443 |
Prednicarbate
|
Hoe 777,Hoe-777,Dermatop E emollient,UNII-V901LV1K7D |
Others
|
|
Prednicarbate (Hoe 777) is a Corticosteroid Hormone Receptor Agonist. Prednicarbate has antipruritic, anti-inflammatory, and vasoconstrictive properties. It also decreases the number of circulating lymphocytes by inhibit... |
|
TP1277 |
Bradykinin
|
|
Endogenous Metabolite
,
Bradykinin Receptor
|
|
Bradykinin is an inflammatory mediator. It is a peptide that causes blood vessels to dilate (enlarge) via the release of prostacyclin, nitric oxide, and Endothelium-Derived Hyperpolarizing Factor. Bradykinin is a physiol... |
|
T4436 |
RO1138452
|
CAY10441 |
Others
,
Prostaglandin Receptor
|
|
RO1138452 (CAY10441) is a selective and orally bioavailable antagonist of prostacyclin receptor (pKi: 8.3). It antagonizes the carbaprostacyclin-induced activation of human neuroblastoma adenylate cyclase, blocking cycli... |
|
T68751 |
Hoe 892
|
|
|
|
Hoe 892 is a stable thia-thimo-analogue of prostacyclin and acts as a platelet aggregation inhibitor. |
|
T10673 |
Carbacyclin
|
Carbaprostacyclin,Carba-PGI2 |
Others
|
|
|
|
T34796 |
TEI-9063
|
TEI9063 |
|
|
TEI-9063 is a stable and highly specific prostacyclin analogue of prostacyclin receptor in mast cell tumor p-815 cells. |
|
T38171 |
Ro 1138452 hydrochloride
|
|
|
|
Selective prostacyclin IP receptor antagonist (pKi = 8.3). Exhibits no affinity at other prostanoid receptors (EP1-4, FP and TP) in a radioligand binding assay. Demonstrates analgesic activity in rats. Orally bioavailabl... |
|
T30426 |
Beraprost
|
ML 1229,MDL 201229,ML-1229,MDL-201229 |
|
|
Beraprost is a stable prostacyclin analog. |
|
T71025 |
KP 10614
|
|
Others
|
|
KP 10614 is a new prostacyclin analog that inhibits platelet-polymorphonuclear leukocyte interaction. |
|
T33579 |
Nafazatrom
|
Nafazatromum |
Others
|
|
Nafazatrom is a pyrazolinone derivative and lipoxygenase inhibitor that increases endogenous prostacyclin (PGI2) and has experimental anticancer activity. Nafazatrom is also an antithrombotic drug that increases prostacy... |
|
T28254 |
OP-2507
|
|
Others
|
|
OP-2507, a prostacyclin agonist, is used potentially for the treatment of hepatic insufficiency and hypertension. |
|
T23657 |
AFP-07
|
AFP07 |
Others
|
|
AFP-07 is a highly selective and potent agonist. It was used for the prostacyclin receptor. |
|
T34417 |
RS 93427-007
|
RS-93427-007,RS93427-007 |
|
|
RS-93427-007 is an orally active stable mimetic agent of prostacyclin for the study of mechanisms of atherogenesis. |
|
T61526 |
Cicaprost
|
|
|
|
Cicaprost (ZK 96480) is a prostacyclin receptor (IP) agonist, which induces relaxation of the artery via concentration-dependent mechanisms. Its EC50 value, determined to be 5.8 nM [1], further highlights its potency. |
|
T15560 |
Iloprost
|
ZK 36374,Ciloprost |
Others
|
|
Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost commonly employed in the treatment of peripheral vascular disease and also indicated in the treatment of patients affected by systemic sclerosis (SSc) in th... |
|
T68639 |
Ciprostene (free base)
|
|
|
|
Ciprostene (free base) is a synthetic, chemically stable analog of prostacyclin (PGI2). In animal models, administration of ciprostene resulted in dose-dependent hypotension, tachycardia, and inhibition of ex vivo ADP-in... |
|
T36212 |
16(S)-Iloprost
|
|
|
|
Iloprost is a second generation structural analog of prostacyclin (PGI2) with about ten-fold greater potency than the first generation stable analogs, typified by carbaprostacyclin. Iloprost binds with equal affinity to ... |
|
T84575 |
U-51605
|
|
Others
|
|
U-51605, a stable analog of the endoperoxide prostaglandin H2 (PGH2), functions as an inhibitor with greater selectivity towards prostacyclin (PGI) synthase over thromboxane (TX) synthase. It also acts as a partial agoni... |
|
T36211 |
16(R)-Iloprost
|
|
|
|
Iloprost is a second generation structural analog of prostacyclin (PGI2) with about ten-fold greater potency than the first generation stable analogs, typified by carbaprostacyclin. Iloprost binds with equal affinity to ... |
|
T37234 |
(±)14(15)-EpETE
|
|
|
|
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-de... |
|
T36552 |
CG 4305
|
|
Others
|
|
Prostacyclin (PGI2) is a cyclooxygenase metabolite with antithrombotic properties found in vascular endothelial cells. The half-life is short both in vivo and in vitro, ranging from 30 seconds to a few minutes. CG 4305 i... |
|
T41251 |
Taprostene
|
|
|
|
Taprostene (CG-4203), a synthetic and chemically stable analogue of Prostacyclin (PGI2), effectively protects the endothelium and myocardium following acute myocardial ischemia and reperfusion in cats. It enhances cytopr... |
|
T70865 |
BMY-42393
|
|
Others
|
|
BMY-42393 is orally active and selective platelet aggregation inhibitor. BMY-42393 is also a prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation (IC50 range 0.3 - 2.0 mic... |
|
T35943 |
15(S)-HpETE
|
|
|
|
15(S)-HpETE is a monohydroperoxy polyunsaturated fatty acid (PUFA) produced by the action of 15-lipoxygenase (15-LO) on arachidonic acid. It is either metabolized to 14,15-leukotriene A4 [1] or reduced to 15(S)-HETE by ... |
|
T37238 |
(±)19(20)-EpDPA
|
|
|
|
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-de... |
|
T37235 |
(±)16(17)-EpDPA
|
(±)16,17-EpDPE,(±)16,17 EDP,(±)16,17-epoxy Docosapentaenoic Acid,(±)16,17-epoxy DPA,(±)16(17)-EpDPA |
Others
|
|
EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-de... |
|
T65598 |
Cefminox sodium
|
|
|
|
Cefminox (Sodium) is a new cephamycin antibiotic possessing a D-amino acid moiety derived from D-cysteine at the C-7B side chain. Cefminox is active against a wide range of bacteria, especially Gram-negative and anaerobi... |
